Skip to main content
. 2016 Dec 20;8(4):6102–6113. doi: 10.18632/oncotarget.14043

Figure 4. PUMA induction by idelalisib is mediated through GSK3β activation.

Figure 4

(A) HCT116 cells were transfected with either a control scrambled siRNA or a GSK3β siRNA for 24 hours, and then treated with 10 μmol/L idelalisib for 6 hours. Nuclear fractions were isolated from cells treated with idelalisib and analyzed for p65 and GSK3β expression by Western blotting. (B) HCT116 cells were transfected with either a control scrambled siRNA or a GSK3β siRNA for 24 hours, and then treated with 10 μmol/L idelalisib for 24 hours. GSK3β and PUMA expression was analyzed by Western blotting. (C) Parental and p53-KD HCT116 cells were treated with 10 μmol/L idelalisib for 24 hours. Total GSK3β and p-GSK3β (S9) expression was analyzed by western blotting. (D) HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. Total AKT and p-AKT expression was analyzed Western blotting. (E) HCT116 cells were transfected with Active AKT plasmid for 8 hours, and then treated with 10 μmol/L idelalisib for 24 hours. PUMA, p-AKT, and total AKT expression was analyzed by Western blotting.